In June 2026, the 28th China International Beauty and Cosmetics Expo (CBE) grandly opened in Shanghai. Micropeptide Biotech, as an ODM/OEM enterprise focusing on efficacy skincare and medical devices, made a major appearance with its core product matrix and innovative solutions.
Cosmetics-Device Combination, Full-Process Innovation Solution
At this exhibition, Micropeptide Biotech highlighted its "cosmetics-device combination" innovation model—deeply integrating Class II medical device-level safety standards with cosmetic efficacy experience, providing brand owners with full-process services from formula R&D and registration filing to finished product production. This model effectively solves the challenge for brand owners in balancing efficacy claim compliance and product experience.
Core Ingredient Technology Highlights
At the booth, the recombinant humanized type III collagen series became the focus. This technology adopts a genetic engineering expression system, with product purity ≥95%, completely identical to the amino acid sequence of human collagen, and excellent biocompatibility. Combined with synergistic formulas of active ingredients such as sodium hyaluronate and peptides, it covers multiple efficacy scenarios including repair, anti-aging, and moisturizing.
Full-Chain Delivery Capability
Micropeptide Biotech owns four major production bases with a total area exceeding 150,000 m², equipped with 6 automated production lines. With more than 110 Class II medical device certificates, GMPC+ISO dual certification system, and 72 patented technologies, it has built a complete delivery capability from raw materials to finished products.
Full-Process Service Capability
From requirement communication, formula R&D, sample confirmation, to mass production, quality inspection, and final delivery, Micropeptide Biotech provides end-to-end full-process services. Brand owners do not need to worry about the trivial details of the production process; our full-process service allows brands to focus on market expansion and sales—leave production to us.
Signing Boom at the Exhibition
During the exhibition, Micropeptide Biotech reached strategic cooperation with multiple brands, with a lively signing atmosphere on site. Brands such as Baiyunshan have all established deep cooperative relationships, with cumulative service to over 800 brands.
Four Major Production Bases
Micropeptide Biotech has laid out four major production bases across the country, forming a production capacity network covering South China and Central China:
- Guangzhou Micropeptide Factory: No. 77, Society 15, Dalang Village, Baiyunhu Street, Baiyun District, Guangzhou City
- Guangdong Micropeptide Factory: No. 18, Taoyuan East Road, Songgang Songxia Industrial Park, Shishan Town, Nanhai District, Foshan City
- Guangdong Jinan Gene Factory: Factory Building 23, Hongguang Industrial Park, No. 2 Wende Fifth Street, Zhaoqing High-tech Zone, Zhaoqing City, Guangdong Province
- Hunan Micropeptide Factory: Room 501, Building 11, Lanyuegu Intelligent Industrial Park, Xieyuan North Road, Ningxiang Economic Development Zone, Changsha City, Hunan Province